Regeneron Pharmaceuticals (REGN) Posts Nearly Four Years Of Survival Benefit Data For Libtayo

Regeneron Pharmaceuticals (NasdaqGS: REGN) reported nearly four year Phase 3 C-POST data for Libtayo in high risk cutaneous squamous cell carcinoma. The C-POST trial showed sustained overall survival and disease free survival benefit for post surgery high risk CSCC patients. Investigators observed that Libtayo's survival benefit remained in place regardless of minimal residual disease status and despite high placebo crossover. Regeneron’s story is broader than Libtayo’s long term C POST...